Two more recent studies comparing clinical outcomes in breast cancer patients with gene expression signatures indicative of PRA or PRB predominance yielded inconsistent results, one showing shorter relapse-free and metastasis-free survival [125] and the other better overall survival [82] in patients with PRB-rich tumors. This evidence concerns the gene RB1 and breast cancer.